Multiple myeloma is a hematologic malignancy of plasma cells in the bone marrow, leading to monoclonal protein production, bone damage, anemia, renal dysfunction, and immunosuppression. It is the most common plasma cell cancer.
MD Anderson researchers developed GT19630, a first-in-class dual-degrader targeting MYC and GSPT1, showing potent preclinical activity in blood cancers including treatment-resistant and TP53-mutated disease. The drug also restored venetoclax sensitivity in resistant AML models.
FDA approved iberdomide (Zenbexus) with daratumumab and dexamethasone for pretreated myeloma. The EXCALIBER-RRMM trial showed a 41% MRD-negative complete response rate vs 21%.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Multiple myeloma immunotherapies like bispecific antibodies and CAR-T cells show high response rates and prolonged survival, but access is hindered by the need for initial hospital stays for bispecifics. Research indicates mezigdomide can reverse T cell exhaustion to boost these therapies, while longer-term CARVYKTI data show significant survival benefits.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Presenters at the 2026 ICE-T Conference discussed the growing role of bispecific antibodies and CAR T-cell therapies in hematologic cancers, while a separate study found that structural instability of linkers in symmetric bispecific antibodies could pose manufacturing hurdles.
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
The FDA accepted Bristol Myers Squibb’s NDAs for iberdomide and mezigdomide, two CELMoD agents for relapsed/refractory multiple myeloma. Iberdomide has Priority Review and a PDUFA date of Aug. 17, 2026; mezigdomide’s is May 13, 2027. The filings are backed by Phase 3 data, including a 52% PFS risk reduction for mezigdomide.
Pfizer's ELREXFIO significantly delayed disease progression in a Phase 3 trial for multiple myeloma, outperforming a standard regimen and strengthening the case for earlier use. Separately, Pfizer completed a real-world study of its lung cancer drug lorlatinib in ROS1-positive NSCLC patients.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07776964 |
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) |
NOT_YET_RECRUITING | NA |
| NCT07774988 |
Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma |
COMPLETED | NA |
| NCT07764861 |
A Open-Label Phase in Participants With Multiple Myeloma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07763054 |
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients |
RECRUITING | |
| NCT07742527 |
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care |
NOT_YET_RECRUITING | PHASE1 |
| NCT07732712 |
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07727668 |
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07691034 |
Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry |
NOT_YET_RECRUITING | |
| NCT07679919 |
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07671287 |
GMMG-HD11/DSMM XXI/64007957MMY3010 |
NOT_YET_RECRUITING | PHASE3 |
